NunaBio

News

20 October 2021

NunaBio Develops Enhanced Sensing Technology

NunaBio Ltd have developed an enhanced sensing platform which is able to distinguish between small differences in a target nucleobase sequence.

The company’s first product is a fluorescence-based technology which greatly enhances the signal. The novel technology gives a specificity and reliability that is currently only possible by whole genome sequencing (WGS) or next generation sequencing (NGS).

The figure below shows how standard fluorescence responses compare to NunaBio's enhanced sensing. There is very little difference in signal intensity between single and double stranded DNA (orange and blue), where the sample is 20bp or less. However, following our enhanced extension process (green), the surface response is much greater and can easily be distinguished.

Enhanced sensing technology

CTO Dr Andrew Pike explains "We believe this enhanced signal per unit area could be simply translated to an array type platform with an increased confidence in distinguishing between two sequences in close proximity."

NunaBio are currently exploring the application of this approach in early disease detection and bacterial analysis.

Working with NunaBio


We work through detail design, integration and initial testing, repeating this process to optimise the design before verification testing.

Our work is fully documented and a package of data and specifications can be assembled to allow scale up manufacture to start smoothly.  

We have extensive experience in Process Validation, Project Management to Phase 2 Manufacturing Criteria, Change Management and Quality Assurance to Regulatory standards (MHRA; FDA). 

Our operations management is led by a Lead Auditor qualified in Quality Management (ISO9001), Medical Devices (ISO13485), Laboratory Testing (ISO17025), Information Security (ISO27001), and Environmental Management (ISO14001).  

Let's talk